Back to Newsroom
Back to Newsroom

Alnylam Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ALNY

Tuesday, 09 April 2024 07:30 AM

Levi & Korsinsky, LLP

NEW YORK, NY / ACCESSWIRE / April 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws.

On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) approved Alnylam's application to expand approval for Onpattro to ATTR-cardiomyopathy (CM) patients. Analysts commenting on the approval noted the FDA was not overly positive and "emphasized the small treatment effects and was seemingly negative on clinical meaningfulness."

Following this news, Alnylam's stock price fell by $18.59 per share, or approximately 4% to close at $193.06 per share.

Further, on October 9, 2023, Alnylam issued a press release announcing that the FDA issued a Complete Response Letter (CRL) as to the Company's "supplemental New Drug Application (sNDA) for patisiran for the treatment of the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis." Alnylam announced that the CRL indicated that "the clinical meaningfulness of patisiran's treatment effects for the cardiomyopathy of ATTR amyloidosis had not been established, and therefore, the sNDA for patisiran could not be approved in its present form." As a result, the Company announced it would no longer pursue an expanded indication for patisiran in the U.S.

Following this news, Alnylam's stock price fell by $2.53 per share, or approximately 2% to close at $165.29 per share.
To obtain additional information, go to:

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212)363-7500.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.


Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212)363-7500
Fax: (212)363-7171

SOURCE: Levi & Korsinsky, LLP

Class Action
Back to newsroom
Back to Newsroom
Share by: